Sunshine Biopharma (SBFM) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Sunshine Biopharma (SBFM) over the last 12 years, with Q3 2025 value amounting to -$883820.0.
- Sunshine Biopharma's Income towards Parent Company rose 2621.32% to -$883820.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 4180.64%. This contributed to the annual value of -$5.1 million for FY2024, which is 1393.84% down from last year.
- According to the latest figures from Q3 2025, Sunshine Biopharma's Income towards Parent Company is -$883820.0, which was up 2621.32% from -$1.8 million recorded in Q2 2025.
- In the past 5 years, Sunshine Biopharma's Income towards Parent Company ranged from a high of $667116.0 in Q4 2021 and a low of -$23.5 million during Q4 2022
- Its 5-year average for Income towards Parent Company is -$2.8 million, with a median of -$1.3 million in 2023.
- As far as peak fluctuations go, Sunshine Biopharma's Income towards Parent Company tumbled by 362447.18% in 2022, and later surged by 9468.35% in 2023.
- Sunshine Biopharma's Income towards Parent Company (Quarter) stood at $667116.0 in 2021, then crashed by 3624.47% to -$23.5 million in 2022, then skyrocketed by 94.68% to -$1.3 million in 2023, then crashed by 72.65% to -$2.2 million in 2024, then surged by 59.05% to -$883820.0 in 2025.
- Its Income towards Parent Company stands at -$883820.0 for Q3 2025, versus -$1.8 million for Q2 2025 and -$1.2 million for Q1 2025.